查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1828014

神經保護市場（依產品類型、作用機制、最終用戶、適應症和通路分類）－2025-2032 年全球預測

Neuroprotection Market by Product Type, Mechanism Of Action, End User, Indication, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年神經保護市場規模將成長至 5,738 億美元，複合年成長率為 7.92%。

主要市場統計數據
基準年2024年 3117.9億美元
預計2025年 3363.1億美元
預測年份：2032年 5738億美元
複合年成長率（%） 7.92%

全面介紹當前的神經保護科學、​​治療方法和戰略重點，為臨床和商業性決策提供資訊

本執行摘要綜合了當今定義神經保護的科學進展、監管動態、商業性促進因素和營運考慮。近幾十年來，人們對神經元存活途徑、發炎連鎖、興奮性毒性損傷和再生策略的理解日益加深；這些生物學見解正與新型治療方法相結合，重塑臨床治療方案。轉化研究如今涵蓋了從傳統的小分子神經保護劑到複雜的生物製藥、基因調節療法和基於細胞的干涉措施，從而形成了一個多方面的格局，其中治療方法差異取決於機制的精確性、遞送技術和患者分層。

隨著相關人員對這些發展趨勢的掌握，重點正從單一目標轉向整合抗發炎控制、抗氧化防禦、離子通道活性調節和神經營養訊號傳遞支援的整合策略。同時，監管機構對安全性、生物標記檢驗和長期療效的期望也要求制定全面的證據生成計劃。因此，決策者必須平衡科學機會與實際考慮因素，例如製造複雜性、通路和臨床治療途徑，以確保創新成果易於獲取並轉化為持續的臨床效益。

科學進步、交付創新和不斷變化的相關人員期望如何從根本上改變臨床和商業性神經保護格局

科學、技術和政策力量的融合正在改變神經保護領域。分子生物學和精準醫療框架的進步使得能夠針對特定病理學機制的標靶治療成為可能，而給藥系統和生物標記主導的試驗設計的改進則提高了證明有意義臨床益處的能力。與科學進步同步，用於遠端監控和自適應臨床試驗方法的數位健康工具的應用正在加速證據生成和患者參與，重塑治療方法從實驗室走向臨床的方式。

此外，新一代治療方法的成本和複雜性促使生物技術、學術中心和合約研究組織之間建立新的夥伴關係結構。這一趨勢正在推動向合作模式的轉變，該模式旨在分散風險、集中專業製造能力，並在開發早期整合監管策略。同時，付款人和醫療保健系統對強力的真實世界證據和經濟價值證明的要求日益提高，這促使研發人員將長期療效、護理路徑整合和上市後績效評估作為其專案規劃的核心組成部分。

評估近期關稅政策如何影響神經保護療法開發中的供應鏈彈性、籌資策略和製造地點決策

貿易措施和關稅相關政策行動的增多，為支持神經保護療法的全球供應鏈帶來了新的複雜性。進口成本的上升可能會擾亂活性藥物成分、生物製藥材料、基因和細胞療法專用試劑以及關鍵包裝零件的採購，從而給籌資策略策略和庫存管理帶來壓力。因此，製造商和供應商正在重新評估供應商冗餘、庫存緩衝和物流路線，以降低生產中斷的風險，同時確保符合低溫運輸和品質要求。

此外，關稅帶來的成本壓力可能會影響製造和灌裝作業選址的策略決策。加快某些製造流程的在獎勵或協商長期供應商協議以穩定投入供應，有實際的激勵措施。對於早期開發商而言，這些動態可能會改變與合作夥伴的談判，因為合約開發商和製造外包可能會根據不斷變化的跨境經濟狀況調整產能分配。這些因素加在一起，要求相關人員將貿易政策情境納入專案級風險評估和採購方案，以維持開發進度和供應的連續性。

詳細的細分情報揭示了產品類型、作用機制、最終用戶、適應症和分銷管道如何相互作用以形成策略和執行

細分分析揭示了不同產品類型和治療方法中存在著微妙的機會和限制。按產品類型分類，該細分市場涵蓋生物製藥、藥品、基因療法、營養保健品和幹細胞療法。在生物製藥領域，單株抗體生物製藥和神經營養因子生物製藥之間的差異決定了其製造的複雜性和監管途徑。在營養保健品領域，此細分市場包括草藥萃取物營養保健品、礦物質營養保健品和維生素營養保健品，每種營養保健品都有不同的實證基礎和分銷動態。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對多發性硬化症患者神經發炎路徑的基因編輯療法的出現
  • 採用穿戴式神經刺激裝置對慢性偏頭痛症狀進行個人化管理
  • 人工智慧驅動的生物標記整合，用於阿茲海默症的早期診斷和進展監測
  • 開發滲透性血腦障壁的小分子用於急性缺血性腦中風干涉
  • 增加對利用神經幹細胞修復脊髓損傷的細胞治療方法的投資
  • 利用脂質奈米顆粒平台對帕金森氏症進行基於RNA的神經保護治療

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章神經保護市場（依產品類型）

  • 生物製藥
    • 單株抗體生技藥品
    • 神經營養因子生物製藥
  • 藥物
    • 胜肽類藥物
    • 小分子藥物
  • 基因治療
  • 營養補充品
    • 草本萃取物膳食補充劑
    • 礦物質營養補充品
    • 維生素營養補充品
  • 幹細胞療法

9. 神經保護市場（依作用機制）

  • 抗發炎藥
    • 細胞激素抑制劑、抗發炎藥
    • NSAID抗發炎藥
    • 類固醇抗發炎藥
  • 抗氧化劑
    • 黃酮類抗氧化劑
    • 維生素C抗氧化劑
    • 維生素E抗氧化劑
  • 鈣離子通道阻斷劑
    • 離胺酸鈣離子通道阻斷劑
    • 尼莫地平鈣離子通道阻斷劑
  • 麩胺酸抑制劑
  • 神經營養因子
  • NMDA拮抗劑
    • 氯胺酮 NMDA 拮抗劑
    • MemantineNMDA拮抗劑

第 10 章神經保護市場（按最終用戶）

  • 診所
  • 家庭醫療保健
  • 醫院
  • 研究機構

第 11 章神經保護市場（按適應症）

  • 阿茲海默症
    • 早期阿茲海默症
    • 中度阿茲海默症
    • 嚴重的阿茲海默症
  • 多發性硬化症
    • 復發型多發性硬化症
    • 進行性性多發性硬化症
  • 帕金森氏症
    • 姿勢不穩帕金森氏症
    • 震顫為主的帕金森氏症
  • 脊髓損傷
  • 中風
    • 出血性中風
    • 缺血性中風
  • 創傷性腦損傷

第 12 章神經保護市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第13章神經保護市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章神經保護市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的神經保護市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Eli Lilly and Company
    • Roche Holding AG
    • Novartis AG
    • AstraZeneca PLC
    • Biogen Inc.
    • Pfizer Inc.
    • AbbVie Inc.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
Product Code: MRR-430D42AA0F33

The Neuroprotection Market is projected to grow by USD 573.80 billion at a CAGR of 7.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 311.79 billion
Estimated Year [2025] USD 336.31 billion
Forecast Year [2032] USD 573.80 billion
CAGR (%) 7.92%

A comprehensive orientation to the current neuroprotection science, therapeutic modalities, and strategic priorities informing clinical and commercial decision-making

This executive summary synthesizes the scientific advances, regulatory dynamics, commercial drivers, and operational considerations defining neuroprotection today. Recent decades have produced a layered understanding of neuronal survival pathways, inflammatory cascades, excitotoxic injury, and regenerative strategies, and these biological insights are converging with new therapeutic modalities to reshape clinical approaches. Translational research now spans traditional small molecule neuroprotectants through complex biologics, gene modulation therapies, and cell-based interventions, creating a multifaceted landscape where therapeutic differentiation depends on mechanism precision, delivery technologies, and patient stratification.

As stakeholders navigate these developments, the emphasis shifts from single-target approaches to integrated strategies that combine anti-inflammatory control, antioxidant defenses, modulation of ion channel activity, and support for neurotrophic signaling. Simultaneously, regulatory expectations for safety, biomarker validation, and long-term outcomes demand integrated evidence generation plans. Therefore, decision-makers must balance scientific opportunity with pragmatic considerations such as manufacturing complexity, distribution channels, and clinical care pathways to ensure that innovation translates to accessible and durable clinical benefit.

How converging scientific advances, delivery innovations, and evolving stakeholder expectations are fundamentally reshaping the clinical and commercial neuroprotection landscape

The neuroprotection landscape is undergoing transformative shifts driven by converging scientific, technological, and policy forces. Advances in molecular biology and precision medicine frameworks are enabling targeted approaches that address specific pathophysiological mechanisms, while improvements in delivery systems and biomarker-driven trial design are enhancing the ability to demonstrate meaningful clinical effect. Alongside scientific evolution, the adoption of digital health tools for remote monitoring and adaptive clinical trial methodologies has accelerated evidence generation and patient engagement, reshaping how therapies move from bench to bedside.

Furthermore, the cost and complexity of next-generation modalities have catalyzed new partnership structures between biotech, academic centers, and contract development organizations. This trend is prompting a reorientation towards collaborative models that distribute risk, concentrate specialized manufacturing capacity, and integrate regulatory strategy earlier in development. In parallel, payers and health systems increasingly demand robust real-world evidence and economic value demonstration, pushing developers to consider long-term outcomes, care pathway integration, and post-market performance measurements as core components of program planning.

Assessment of how recent tariff policies are influencing supply chain resilience, procurement strategy, and manufacturing location decisions across neuroprotective therapeutic development

Elevated trade measures and tariff-related policy actions have introduced new layers of complexity to global supply chains supporting neuroprotective therapeutics. The sourcing of active pharmaceutical ingredients, biologic raw materials, specialized reagents for gene and cell therapies, and critical packaging components can be disrupted by increased import costs, creating pressure on procurement strategies and inventory management. As a result, manufacturers and suppliers are reevaluating supplier redundancy, inventory buffers, and logistics routing to mitigate the risk of production interruptions while preserving compliance with cold-chain and quality requirements.

In addition, tariff-driven cost pressures can influence strategic decisions about where to situate manufacturing and fill-finish operations. There is an observable incentive to accelerate localization of certain production steps or to negotiate long-term supplier agreements to stabilize input availability. For early-stage developers, these dynamics may alter partnering conversations, because contract development and manufacturing organizations may shift capacity allocation in response to changes in cross-border economics. Collectively, these factors demand that stakeholders integrate trade policy scenarios into program-level risk assessments and procurement playbooks to preserve development timelines and maintain supply continuity.

In-depth segmentation intelligence revealing how product types, mechanisms of action, end users, indications, and distribution channels interact to shape strategy and execution

Segmentation analysis reveals nuanced opportunities and constraints across product types and therapeutic approaches. Based on Product Type, the landscape spans Biologics, Drugs, Gene Therapy, Nutraceuticals, and Stem Cell Therapy. Within Biologics the differentiation between Monoclonal Antibody Biologics and Neurotrophic Factor Biologics determines manufacturing complexity and regulatory pathways, while Drugs encompass Peptide Drugs and Small Molecule Drugs with distinct delivery considerations and formulation challenges. Nutraceuticals extend into Herbal Extract Nutraceuticals, Mineral Nutraceuticals, and Vitamin Nutraceuticals, each carrying different evidentiary expectations and distribution dynamics, and Stem Cell Therapy presents unique infrastructure and regulatory oversight requirements.

Based on Mechanism Of Action, the field incorporates Anti Inflammatory Agents, Antioxidants, Calcium Channel Blockers, Glutamate Inhibitors, Neurotrophic Factors, and NMDA Antagonists. Anti Inflammatory Agents are further categorized into Cytokine Inhibitor Anti Inflammatory Agents, NSAID Anti Inflammatory Agents, and Steroid Anti Inflammatory Agents, which influence safety monitoring and chronic use considerations. Antioxidant strategies include Flavonoid Antioxidants, Vitamin C Antioxidants, and Vitamin E Antioxidants, each with different pharmacokinetic and formulation profiles. Within Calcium Channel Blockers, distinctions between Flunarizine Calcium Channel Blockers and Nimodipine Calcium Channel Blockers affect clinical application, while NMDA Antagonists subdivide into Ketamine NMDA Antagonists and Memantine NMDA Antagonists, reflecting divergent dosing paradigms and therapeutic contexts.

Based on End User, the primary care contexts include Clinics, Home Healthcare, Hospitals, and Research Institutes, each presenting distinct procurement cycles, storage capabilities, and lifecycle management demands. Based on Indication, therapeutic targeting spans Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Spinal Cord Injury, Stroke, and Traumatic Brain Injury, with granular subpopulations such as Early Stage Alzheimer's Disease, Moderate Stage Alzheimer's Disease, Severe Stage Alzheimer's Disease, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Postural Instability Parkinson's Disease, Tremor Dominant Parkinson's Disease, Hemorrhagic Stroke, and Ischemic Stroke informing clinical trial design and outcome selection. Based on Distribution Channel, suppliers must consider the practicalities of Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies when devising launch and access strategies.

Taken together, these segmentation insights underscore the importance of aligning development strategy with the specific regulatory, logistical, and clinical realities of each therapeutic and distribution pathway. Cross-segment synergies, such as pairing neurotrophic factor biologics with targeted delivery systems for defined indication subtypes, can create differentiated value propositions when matched to the operational capacities of end users and distribution channels.

Regional strategic implications across major geographies that influence regulatory planning, manufacturing footprint decisions, clinical operations, and access pathways

Regional dynamics are critical for sculpting commercial strategy, clinical trial design, manufacturing footprint, and regulatory engagement. The Americas continue to be a focal point for advanced clinical development and commercialization given established payer structures and high-density research infrastructure, but regional reimbursement nuances and procurement processes require tailored value dossiers and evidence packages. In Europe, Middle East & Africa, regulatory harmonization trends and country-specific health technology assessment practices necessitate early alignment on endpoints and budget impact considerations, and emerging markets within the region may present opportunities for real-world data collection and post-authorization access programs.

Asia-Pacific presents a diverse environment where regulatory maturity varies widely and where local manufacturing and contract development capabilities can offer strategic advantages. In many countries across the region, initiatives to accelerate domestic capacity for biologics and advanced therapies can shorten supply chain routes and reduce exposure to cross-border trade friction. Therefore, biopharmaceutical leaders should deploy differentiated strategies that account for regional regulatory ecosystems, distribution infrastructure, and payer expectations, while proactively engaging local clinical and manufacturing partners to optimize trial recruitment, localization of supply, and long-term access.

Competitive and collaborative company-level trends highlighting platform investments, strategic alliances, and specialized manufacturing capabilities driving therapeutic advancement

The competitive and collaborative landscape in neuroprotection is characterized by a mix of established pharmaceutical companies, specialized biotechnology firms, academic translational centers, and contract service providers. Key organizations are concentrating on platform technologies for targeted delivery, modular manufacturing for biologics and cell therapies, and translational biomarker programs that can de-risk late-stage development. Partnerships between innovators and large-scale manufacturers are increasingly common to reconcile the capital intensity of complex therapeutic production with the need for scalable supply chains.

Moreover, research institutes and clinical networks are acting as crucial nodes for validating novel mechanisms and enabling adaptive trial designs that prioritize patient-relevant endpoints. Strategic alliances that combine deep mechanistic expertise with commercialization capabilities can accelerate time-to-access while managing development risk. In parallel, contract research and manufacturing organizations that invest in specialized cleanroom facilities, cold-chain logistics, and regulatory support services are becoming essential enablers for companies seeking to commercialize advanced neuroprotective modalities at scale.

Practical strategic recommendations for senior leaders to align scientific investment, supply chain resilience, and value demonstration in neuroprotective therapy development

Industry leaders should adopt an integrated approach that aligns scientific prioritization with pragmatic supply chain, regulatory, and commercial planning. First, organizations must prioritize cross-functional scenario planning that incorporates regulatory pathway contingencies, supplier continuity plans, and reimbursement evidence strategies to reduce program vulnerability. Early investment in biomarker validation and real-world evidence frameworks will enhance the persuasiveness of clinical claims and payor discussions, particularly for therapies that rely on surrogate endpoints or novel mechanisms.

Second, forging selective partnerships with contract development and manufacturing organizations, academic translational hubs, and commercialization specialists can distribute risk while concentrating internal resources on core scientific differentiators. Third, companies should consider regional manufacturing or licensed local supply arrangements to mitigate trade-related disruptions and to expedite access in jurisdictions with distinct regulatory or procurement processes. Finally, a sustained focus on post-approval performance measurement, patient adherence support, and outcomes-based contracting will be critical to securing long-term access and demonstrating value to health systems and payers.

Transparent description of primary and secondary research methods, evidence synthesis approaches, and validation steps used to generate practical neuroprotection insights

This research synthesis combines primary interviews with clinical investigators, manufacturing and procurement leaders, regulatory specialists, and commercial strategists together with systematic secondary literature review of peer-reviewed translational science, regulatory guidance documents, and published clinical trial methodology. Evidence synthesis emphasized mechanism-specific clinical outcomes, manufacturing process dependencies, and care delivery pathway considerations to ensure that insights reflect operational as well as scientific realities.

Analytical methods included qualitative triangulation across stakeholder perspectives, scenario analysis to assess supply chain and policy sensitivities, and comparative evaluation of regulatory pathways relevant to biologics, small molecules, gene therapies, and cell-based interventions. Data quality controls included source cross-validation, investigator corroboration of clinical assumptions, and iterative validation with subject matter experts to ensure the robustness and applicability of recommendations for decision-makers.

Synthesis of strategic imperatives that connect translational science, operational resilience, and evidence-generation to realize clinical impact in neuroprotection

In conclusion, neuroprotection is entering an era where mechanistic precision, delivery innovation, and integrated evidence strategies are converging to create differentiated clinical opportunities. Success will depend on the capacity to translate laboratory insights into robust clinical programs while simultaneously managing the operational realities of complex manufacturing, distributed supply chains, and payer expectations. Stakeholders who align early on biomarker strategies, regional manufacturing considerations, and partnership models are better positioned to mitigate development risk and to accelerate clinical impact.

Looking forward, the interplay between scientific novelty and pragmatic execution will determine which therapies achieve durable clinical adoption. By embedding regulatory foresight, procurement resilience, and real-world performance measurement into program design, organizations can enhance the probability that promising neuroprotective interventions will reach the patients who need them most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of gene editing therapies targeting neuroinflammation pathways in multiple sclerosis patients
  • 5.2. Adoption of wearable neurostimulation devices for personalized management of chronic migraine symptoms
  • 5.3. Integration of AI-driven biomarkers for early Alzheimer's disease diagnosis and progression monitoring
  • 5.4. Development of blood-brain barrier-penetrant small molecules for acute ischemic stroke intervention
  • 5.5. Rising investment in cell-based therapies harnessing neural stem cells for spinal cord injury repair
  • 5.6. Utilization of lipid nanoparticle platforms for RNA-based neuroprotective treatment in Parkinson's disease

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuroprotection Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Monoclonal Antibody Biologics
    • 8.1.2. Neurotrophic Factor Biologics
  • 8.2. Drugs
    • 8.2.1. Peptide Drugs
    • 8.2.2. Small Molecule Drugs
  • 8.3. Gene Therapy
  • 8.4. Nutraceuticals
    • 8.4.1. Herbal Extract Nutraceuticals
    • 8.4.2. Mineral Nutraceuticals
    • 8.4.3. Vitamin Nutraceuticals
  • 8.5. Stem Cell Therapy

9. Neuroprotection Market, by Mechanism Of Action

  • 9.1. Anti Inflammatory Agents
    • 9.1.1. Cytokine Inhibitor Anti Inflammatory Agents
    • 9.1.2. NSAID Anti Inflammatory Agents
    • 9.1.3. Steroid Anti Inflammatory Agents
  • 9.2. Antioxidants
    • 9.2.1. Flavonoid Antioxidants
    • 9.2.2. Vitamin C Antioxidants
    • 9.2.3. Vitamin E Antioxidants
  • 9.3. Calcium Channel Blockers
    • 9.3.1. Flunarizine Calcium Channel Blockers
    • 9.3.2. Nimodipine Calcium Channel Blockers
  • 9.4. Glutamate Inhibitors
  • 9.5. Neurotrophic Factors
  • 9.6. NMDA Antagonists
    • 9.6.1. Ketamine NMDA Antagonists
    • 9.6.2. Memantine NMDA Antagonists

10. Neuroprotection Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Neuroprotection Market, by Indication

  • 11.1. Alzheimer's Disease
    • 11.1.1. Early Stage Alzheimer's Disease
    • 11.1.2. Moderate Stage Alzheimer's Disease
    • 11.1.3. Severe Stage Alzheimer's Disease
  • 11.2. Multiple Sclerosis
    • 11.2.1. Relapsing Remitting Multiple Sclerosis
    • 11.2.2. Secondary Progressive Multiple Sclerosis
  • 11.3. Parkinson's Disease
    • 11.3.1. Postural Instability Parkinson's Disease
    • 11.3.2. Tremor Dominant Parkinson's Disease
  • 11.4. Spinal Cord Injury
  • 11.5. Stroke
    • 11.5.1. Hemorrhagic Stroke
    • 11.5.2. Ischemic Stroke
  • 11.6. Traumatic Brain Injury

12. Neuroprotection Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Neuroprotection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neuroprotection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neuroprotection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Eli Lilly and Company
    • 16.3.2. Roche Holding AG
    • 16.3.3. Novartis AG
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Biogen Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Johnson & Johnson
    • 16.3.9. Merck & Co., Inc.
    • 16.3.10. GlaxoSmithKline plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEUROPROTECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL NEUROPROTECTION MARKET SIZ